Skip links

HILOPRO®

mAb + Hilopro = SubQ

The HILOPRO® technology uses patented platform technology with GRAS excipients to enable innovator mAbs and biosimilars for SubQ delivery, optimized dosing, and enhanced market acceptance.

​ This single formulation technology works for a wide range of monoclonal antibodies, supports multiple dosing and delivery options, providing greater flexibility and optimal patient convenience.

Innovation Backed by Data

High concentration, low viscosity, and low volume dosing open entirely new delivery possibilities.

Hilopro Tech enables biotherapeutics companies to expand their market share and maximize value creation through product life extension.

Comparison Chart

Trastuzumab

Concentration: Viscosity achieved using BRL's Technology
Concentration : 250mg/mL
Viscosity: 14 cP

Etanercept

Concentration: Viscosity achieved using BRL's Technology
Concentration : 200mg/mL
Viscosity: 23 cP

Bevacizumab

Concentration: Viscosity achieved using BRL's Technology
Concentration : 250mg/mL
Viscosity: 14 cP

Cetuximab

Concentration: Viscosity achieved using BRL's Technology
Concentration : 200mg/mL
Viscosity: 28 cP

Rituximab

Concentration: Viscosity achieved using BRL's Technology
Concentration : 225mg/mL
Viscosity: 20 cP

Human Gamma Globulin

Concentration: Viscosity achieved using BRL's Technology
Concentration : 250mg/mL
Viscosity: 17 cP

Why HILOPRO®

Our safe technology comes with benefits that no other innovation has been able to deliver.

Reduced Time & Cost

Reduced Time & Cost

Reduce cost by enabling at-home administration, minimal hospital visits, and enhancing the quality of life.

No or Zero Side Effects

No or Zero Side Effects

Uses GRAS excipients without adverse side effects or toxicity.

Cost-effective

Cost-effective

Less licensing fees compared to Halozyme’s ENHANZE® Technology.

Validation

Validation

Technology is validated by four major players in the biopharma industry

Easy to Adapt

Easy to Adapt

Our technology comprises two GRAS (Generally Regarded As Safe) category excipients approved by the US FDA.

Patent Protected

Patent Protected

Hilopro is a patent protected technology filed in 6 jurisdictions; a patent approved in the US jurisdiction.

Cutting Edge Technology

Cutting Edge Technology

BRL's High Concentration Protein Formulation Technology with its GRAS excipients outperformed all other published buffer and excipient combinations, resulting in high concentration formulations with significantly lower viscosity.

Proof of concept for your mAb in 8 Weeks!

High concentration, low viscosity, and low-volume dosing open entirely new delivery possibilities. Hilopro Tech enables biotherapeutics companies to expand their market share and maximize value creation through product life extension.

Disclaimer: All trademarks, logos, and brand names are the property of their respective owners. All company, product, and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.

Explore
Drag